DIETMAR HOPP ESTABLISHES SPECIALIZED PHARMACEUTICAL COMPANY IN HEIDELBERG

A specialized pharmaceutical company has emerged from Axaron Bioscience AG and LION bioscience AG. The new pharma specialist for central nervous system (CNS) diseases has funds of approximately EUR 51 million, of which EUR 21 million is being provided by the Hopp family. The majority shareholder of Axaron Bioscience AG, BASF Aktiengesellschaft in Ludwigshafen, will invest EUR seven million in the new company.

Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5037/282/)